J Med Cases

Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc

Journal website https://jmc.elmerpub.com

Case Report

Volume 17, Number 8, August 2026, pages 371-375

A Delicate Balance: Immunotherapy for Endometrial Cancer in a Patient With Multiple Sclerosis

Figure

↓ Figure 1. Longitudinal multidisciplinary management timeline. The figure illustrates the clinical timeline of oncological treatment, neurological monitoring (clinical examination and MRI at baseline, 6 and 12 months), and decision points regarding disease-modifying therapy management. The monitoring strategy was based on available observational evidence and expert consensus rather than formal guidelines. DMTs: disease-modifying therapies; MRI: magnetic resonance imaging.

Table

↓ **Table 1.** Published Experience of Immune Checkpoint Inhibitors in Patients With MS
Study	Cancer type	ICI	MS status	DMT management	Neurological outcome
Overview of selected published reports and cohorts describing ICI use in patients with MS. MS: multiple sclerosis; DMTs: disease-modifying therapies; ICIs: immune checkpoint inhibitors; PD-1: programmed cell death protein 1; PD-L1: programmed death-ligand 1; RRMS: relapsing-remitting MS; SPMS: secondary progressive MS; MRI: magnetic resonance imaging.
Androdias et al, 2024 [7]	Various	Anti–PD-1/PD-L1	RRMS/SPMS	DMT discontinued in most	17% MS activity, mainly younger patients
Gelipter et al, 2024 [8]	Various	Mixed ICIs	Mixed	Variable	Low relapse rate overall
Present case	Endometrial cancer	Dostarlimab	RRMS	Ozanimod discontinued	No relapse or MRI activity at 12 months